We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04259944
Recruitment Status : Active, not recruiting
First Posted : February 7, 2020
Last Update Posted : July 27, 2022
Sponsor:
Collaborator:
Guardant Health, Inc.
Information provided by (Responsible Party):
IFOM, The FIRC Institute of Molecular Oncology

Tracking Information
First Submitted Date  ICMJE February 5, 2020
First Posted Date  ICMJE February 7, 2020
Last Update Posted Date July 27, 2022
Actual Study Start Date  ICMJE June 16, 2020
Estimated Primary Completion Date July 15, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 5, 2020)
Number of post-surgery and post-adjuvant false negative cases after a double ctDNA-negative detection [ Time Frame: 2 years ]
Cases that become positive at subsequent interventional LB or that experience radiological relapse
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 5, 2020)
  • Disease-Free Survival (DFS) [ Time Frame: 2 & 3 years ]
  • Overall Survival (OS) [ Time Frame: 5 years ]
  • Safety and tolerability according to CTCAE version 5.0 [ Time Frame: 2 years ]
  • Assessment of QLQ-C30 and CR-29 EORTC questionnaires [ Time Frame: 2 years ]
  • Number of patients experiencing ctDNA seroconversion (i.e. ctDNA+ that become ctDNA-) after any chemotherapy regimen remaining disease free [ Time Frame: 2 & 3 years ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
Official Title  ICMJE Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
Brief Summary PEGASUS is a prospective multi-centric study designed to prove the feasibility of using liquid biopsy to guide the post-surgical and post-adjuvant clinical management in 140 microsatellite stable Stage-III and T4N0 Stage-II colon cancer patients.
Detailed Description

The LUNAR1 Test (Guardant Health, Redwood City, CA, USA) will be used for ctDNA determination. For the efficacy analysis, the PEGASUS cohort will be compared with a cohort of 420 patients from the TOSCA trial (NCT00646607) population matched 3:1 for all known prognostic phenotypes.

A post-surgical LB executed 2-4 weeks after surgery will guide a "Molecular Adjuvant" treatment as follows: i) ctDNA+ patients will receive CAPOX for 3 months; ii) ctDNA- patients will receive capecitabine (CAPE) for 6 months but will be retested after 1 cycle, and if found ctDNA+ will be switched to CAPOX treatment.

Immediately after the end of the "Molecular Adjuvant" treatment a further LB will be performed and instruct subsequent treatment. Positive patients (ctDNA+/+ and ctDNA-/+) will receive an up-scaled "Molecular Metastatic" systemic treatment for 6 months or until radiological progression or toxicity as follows: i) ctDNA+/+ patients will be treated with FOLFIRI; ii) ctDNA-/+ patients with CAPOX. These patients will be subjected to a LB after 3 months at the end of treatment and in case of positivity will be switched to FOLFIRI.

Patients experiencing ctDNA conversion to negative (ctDNA+/-) will receive a de-escalated treatment with CAPE for 3 months. 3 LB will be performed within 3 months and in case of positivity the patient will be switched to FOLFIRI. Patients with ctDNA-/- will be subjected to an interventional follow-up comprising 2 further LB and in case of positivity they will be switched to CAPOX treatment. PEGASUS is piggybacked to AlfaOmega (NCT04120935), a Master Observational Protocol that will follow patients from diagnosis to 5 years or recurrence/death (whichever comes first), collecting clinical data, radio-images and biological samples. AlfaOmega provides a clinical and logistic ecosystem for the seamless integration of PEGASUS clinical results with the biological underpinning of colon cancer.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Colon Cancer
Intervention  ICMJE
  • Drug: CAPOX

    DAY 1

    • OXA 130 mg/m2 administered as intravenous infusion over 2 hours in 250 mL dextrose 5%
    • CAPE 1000 mg/m2 administrated per os twice daily

    DAY 2-14

    • CAPE 1000 mg/m2 os twice daily

    Cycle length is 3 weeks comprising 2 hours of oxaliplatin infusion every 21 days, 14 days of oral capecitabine and 7 days of resting.

  • Drug: Capecitabine

    DAY 1-14

    • CAPE 1250 mg/m2 os twice daily

    Cycle length is 3 weeks comprising 14 days of oral capecitabine and 7 days of resting.

  • Drug: FOLFIRI

    Day 1:

    • IRI, 180 mg/m2 administered as iv infusion over 30-90 minutes in 250 mL dextrose 5%, concurrently (via a Y-connector) with
    • LV, 400 mg/m2 administered as an iv infusion over 2 hours, in 250 mL dextrose 5%, followed by
    • 5-FU, 400 mg/m2 administered as a bolus injection (iv push administered by hand) and then at 2400 mg/m2 administered as a iv infusion over 46 hours.

    Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest.

Study Arms  ICMJE Experimental: Liquid Biopsy-Guided Adjuvant Treatment

A post-surgical LB executed 2-4 weeks after surgery will guide a "Molecular Adjuvant" treatment:

  • ctDNA+ patients: CAPOX for 3 months
  • ctDNA- patients: capecitabine (CAPE) for 6 months. LB after 1 cycle and if found ctDNA+ will be switched to CAPOX.

A post-Molecular Adjuvant treatment LB will be performed and instruct subsequent treatment:

  • ctDNA+/+ patients: up-scale to a "Molecular Metastatic" treatment with FOLFIRI for 6 months or until radiological progression or toxicity;
  • ctDNA-/+ patients: up-scale to a "Molecular Metastatic" treatment with CAPOX for 6 months or until radiological progression or toxicity. LB after 3 months at the end of treatment and in case of positivity switch to FOLFIRI.
  • ctDNA+/- patients: de-escalate treatment to CAPE for 3 months. 3 LB performed within 3 months and in case of positivity switch to FOLFIRI.
  • ctDNA-/- patients: interventional follow-up comprising 2 further LB and in case of positivity switch to CAPOX treatment.
Interventions:
  • Drug: CAPOX
  • Drug: Capecitabine
  • Drug: FOLFIRI
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: February 5, 2020)
140
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE October 15, 2024
Estimated Primary Completion Date July 15, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Pegasus trial written informed consent.
  • Age ≥ 18 years.
  • Histologically confirmed diagnosis of operable stage III or T4N0 stage II colon cancer located 12 cm from the anal verge by endoscopy and above the peritoneal reflection at surgery.
  • Availability of plasma collected prior to surgery.
  • Availability of the original FFPE tumor tissue.
  • Acceptance to undergo at least all the interventional liquid biopsies.
  • ECOG performance status 0-1.
  • Normal organ functions. (as defined in section 9.3)
  • Women with childbearing potential should complete a pregnancy test and be willing to use highly effective contraceptive methods.

Exclusion Criteria:- Patients having a MSI-H/MMRd tumor are excluded from the study (done according to standard clinical practice).

  • History of another neoplastic disease, unless in remission for ≥ 5 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
  • Had an incomplete diagnostic colonoscopy and/or polyps removal.
  • Macroscopic or microscopic evidence of residual tumor (R1 or R2 resections). Patients should never have had any evidence of metastatic disease (including presence of tumor cells in the peritoneal lavage).
  • Current or recent treatment with another investigational drug or participation in another investigational study
  • Patient unable to comply with the study protocol owing to psychological, social or geographical reasons.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.
  • Inadequate contraception (male or female patients) if of childbearing or procreational potential.
  • Clinically relevant cardiovascular disease.
  • Acute or subacute intestinal occlusion or history of inflammatory bowel disease.
  • Pre-existing neuropathy > grade 1. Known grade 3 or 4 allergic reaction to any of the components of the treatment.
  • Has a known DPD (DihydroPyrimidine Dehydrogenase) deficiency.
  • Has a known Gilbert Syndrome or UGT1A1 homozygous *28/*28 germline variant.
  • Has a known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is required.
  • Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
  • Has a known history of active TB (Bacillus Tuberculosis).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Italy,   Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04259944
Other Study ID Numbers  ICMJE IFOM-CPT005/2019/PO004
2019-002074-32 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party IFOM, The FIRC Institute of Molecular Oncology
Original Responsible Party Same as current
Current Study Sponsor  ICMJE IFOM, The FIRC Institute of Molecular Oncology
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Guardant Health, Inc.
Investigators  ICMJE
Study Chair: Sara Lonardi, MD Istituto Oncologico Veneto IRCCS
PRS Account IFOM, The FIRC Institute of Molecular Oncology
Verification Date July 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP